Publication

Vaccination with designed neopeptides induces intratumoral, cross-reactive CD4+ T cell responses in glioblastoma.

Journal Paper/Review - Oct 13, 2022

PubMed
Doi
Contact

Citation
Wang J, Weiss T, Neidert M, Toussaint N, Naghavian R, Moreno Sellés C, Foege M, Tomas Ojer P, Medici G, Jelcic I, Schulz D, Rushing E, Dettwiler S, Schrörs B, Shin J, McKay R, Wu C, Lutterotti A, Sospedra M, Moch H, Greiner E, Bodenmiller B, Regli L, Weller M, Roth P, Martin R. Vaccination with designed neopeptides induces intratumoral, cross-reactive CD4+ T cell responses in glioblastoma. Clin Cancer Res 2022
Type
Journal Paper/Review (English)
Journal
Clin Cancer Res 2022
Publication Date
Oct 13, 2022
Issn Electronic
1557-3265
Brief description/objective

The low mutational load of some cancers is considered one reason for the difficulties to develop effective tumor vaccines. To overcome this problem, we developed a strategy to design neopeptides through single amino acid mutation to enhance their immunogenicity.